Ditan Hospital, Capital Medical University, Center of Integrative Medicine, China; 19 Institute of Infection and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Infectious Diseases, China; 20 Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Department of Infectious Diseases, China; 21 Shanghai Public Health Clinical Centre, Fudan University, Department of Liver Intensive Care Unit, China; 22 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, China; 23 Ren Ji Hospital, School of Medicine, Shanghai JiaoTong University. Shanghai Institute of Digestive Disease, Key Laboratory of Gastroenterology & Hepatology, Chinese Ministry of Health (Shanghai Jiao Tong University), Department of Gastroenterology, China Email: haili_17@126.com Background and Aims: Portal vein thrombosis (PVT) is a common and serious complication in cirrhotic patients. However, little is known about PVT in cirrhotic patients with acute decompensation (AD). We investigated the prevalence and clinical significance of PVT in nonmalignant cirrhotic patients with AD. Method: Patients came from two prospective multicenter cohorts of patients with acute exacerbation of chronic liver disease, named CATCH-LIFE (NCT02457637 and NCT03641872), established by the Chinese Chronic Liver Failure Consortium from January 2015 to December 2016 and July 2018 to January 2019. The prevalence, clinical manifestations and risk factors of PVT in cirrhotic patients with AD were analyzed. Results: The prevalence of PVT in cirrhotic patients with AD was 9.36%, significantly higher than those without AD (5.24%) (p = 0.04). Compared to cirrhotic AD patients without PVT, patients with PVT had a significantly higher incidence of variceal bleeding (47.33% vs 19.63%, p < 0.001) and a higher serum level of D-dimer (p < 0.001). Splenectomy, invasive procedures were independent risk factors for PVT in cirrhotic AD patients. The short- and long-term mortality rates of cirrhotic AD patients were significantly higher than those without AD ( p < 0.001). But among cirrhotic AD patients, the short- and long- term mortality rates were similar between patients with PVT and without PVT. Conclusion: Cirrhotic patients with AD had a significant elevated prevalence of PVT. The occurrence of PVT promoted portal hyper- tension and variceal bleeding, thus would increase the risk for mortality as a result of the development of AD. It would be beneficial to improve portal hypertension through regular screening and preventing PVT in cirrhotic patients. SAT146 Pre-emptive (early) transjugular intrahepatic porto-systemic shunt in the treatment of high-risk acute variceal bleeding. An individual patient data meta-analysis Juan Carlos Garcia Pagan 1,2,3 , Oana Nicoara-Farcau 4,5 , Debora Angrisani 1 , Alberto Monescillo 6 , Guohong Han 7,8 , Ferran Torres 2,9,10 , Jaime Bosch 1,2,11 , Georgina Casanovas 2,9 , Yong Lv 12 , Daiming Fan 7,13,14 , Christophe Bureau 15,16 , Frederik Nevens 17,18 , Karel Caca 19 , Angelo Luca 20 , Alexander Zipprich 21 , Bogdan Procopet 4,5 , Alvaro Giraldez-Gallego 22 , Lucio Amitrano 23 , Candid Villanueva 24 , Dominique Thabut 25 , Luis Ibañez 26 , Jonel Trebika 27,28,29,30 , Joan Genesca 31,32 , Jose María Palazon 33 , José Castellote Alonso 34 , Susana G. Rodrigues 35,36 , Lise Lotte Gluud 37,38 , Prof. Dr. Arnulf Ferlitsch 39 , Carlos Alberto Costa Noronha Ferreira 40 , Jose Luis Mundi 41 , Henning Grønbæk 42 , Romano Sassatelli 43 , Alessandra Dell’Era 44 , Marco Senzolo 45 , Manuel Romero Gomez 46 , Manuel Hernández Guerra 47 , Meritxell Casas 48 , Massimo Primignani 49 , Aleksander Krag 28 , José Luis Calleja Panero 50 , Nuria Cañete 51 , Helena Masnou 52 , Joachim Mössner 53 , Virginia Hernandez-Gea 1,2,3 . 1 Hospital Clinic, Hepatic Hemodynamic Laboratory, Liver Unit, Barcelona, Spain; 2 Institut D’Investigacions Biomédiques August Pi i Sunyer, Barcelona, Spain; 3 Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain; 4 Regional Institute of Gastroenterology and Hepatology “Octavian Fodor,” Hemodynamic Laboratory, Hepatology Department, Cluj-Napoca, Romania; 5 “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania; 6 Hospital Universitario Insular de Gran Canaria, Digestive Disease Department, Las Palmas, Spain; 7 National Clinical Research Center for Digestive Diseases, Xi’an, China; 8 Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Department of Liver Diseases and Digestive Interventional Radiology; 9 Hospital Clinic, Medical Statistics Core Facility, Barcelona, Spain; 10 Universitat Autònoma de Barcelona, Biostatistics Unit, Barcelona, Spain; 11 University Clinic for Visceral Surgery and Medicine, Hepatology, Bern, Swaziland; 12 Xijing Hospital of Digestive Diseases, Department of Liver Diseases and Digestive Interventional Radiology, Xi’an, China; 13 Xijing Hospital of Digestive Diseases, State Key Laboratory of Cancer Biology, Xi’an, China; 14 Fourth Military Medical University, Xi’an, China; 15 Centre Hospitalier Universitaire Purpan, Service d’Hépatogastro-entérologie, Toulouse, France; 16 Université 3 Paul Sabatier, Toulouse, France; 17 University Hospital Gasthuisberg, Department of Hepatology, Leuven, Belgium; 18 Katholieke Universiteit, Leuven, Belgium; 19 Klinikum Ludwigsburg, Medizinische Klinik I, Ludwigsburg, Germany; 20 Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT), Palermo, Italy; 21 Martin Luther Universität Halle-Wittenberg Klinik, Halle, Germany; 22 University Hospital Virgen del Rocío, Digestive Diseases Department, Seville, Spain; 23 Ospedale ACardarelli, Gastroenterology Unit, Naples, Italy; 24 Hospital de la Santa Creu i Sant Pau and CIBERehd, Servei de Patologia Digestiva, Barcelona, Spain; 25 Groupement Hospitalier Pitié-Salpêtrie ̀ re- Charles Foix, Paris, France; 26 Hospital General Universitario Gregorio Marañón, liSGM, CIBERehd, Servicio de Medicina de Aparato Digestivo Gregorio Marañón, Barcelona, Spain; 27 University of Bonn, Medical Department I, Bonn, Germany; 28 Odense University Hospital, Department of Gastroenterology and Hepatology, Odense, Denmark; 29 Institute for Bioengineering of Catalonia, Barcelona, Spain; 30 European Foundation for the Study of Chronic Liver Failure (EF-Clif), Barcelona, Spain; 31 Hospital Universitari Vall d’Hebron, Department of Gastroenterology, Barcelona, Spain; 32 Vall d’Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona and CIBERehd, Barcelona, Spain; 33 Hospital General Universitario de Alicante, Alicante, Spain; 34 Hospital Universitari de Bellvitge, Gastroenterology Department, Hepatology Unit, Barcelona, Spain; 35 Centro Hospitalar São João, Gastroenterology and Hepatology Department, Porto, Portugal; 36 Inselspital, Bern University, Swiss Liver Center, Bern, Swaziland; 37 University Hospital of Hvidovre, Gastrounit, Medical Division, Copenhagen, Denmark; POSTER PRESENTATIONS S723 Journal of Hepatology 2020 vol. 73 | S653–S915